SIMPONI(R)* (golimumab) Receives Health Canada Approval for Ulcerative Colitis
First and Only Subcutaneous Biologic Treatment Approved to Reduce Signs and
Symptoms, Achieve Sustained Clinical Remission and Improve Appearance of the
Mucosa During Induction
TORONTO, Sept. 24, 2013 /CNW/ - Janssen Inc. announced today that Health
Canada has approved SIMPONI(®) (golimumab) for the treatment of moderately to
severely active ulcerative colitis (UC). SIMPONI(®) is the first and only
subcutaneously administered anti-tumor necrosis factor (TNF)-alpha therapy
approved in Canada to reduce signs and symptoms, induce clinical remission,
achieve sustained clinical remission in induction responders and improve
endoscopic appearance of the mucosa during induction in adult patients with
moderately to severely active UC who have had an inadequate response to
"This approval is an important advance in the treatment of ulcerative colitis.
In clinical studies, golimumab was shown to induce rapid and continuous
clinical response in symptom control, which may help to optimize patient
outcomes," said Dr. Brian Feagan, Professor of Medicine and Epidemiology and
Biostatistics at the Western University in London, Ontario, and an expert in
the field of inflammatory bowel disease. "In addition, self-administered
subcutaneous delivery provides some physicians and patients with an option to
tailor treatment based on individual circumstances."
Ulcerative colitis is a chronic inflammatory bowel disease (IBD) marked by
ulcers in the lining of the colon.(2)Canada has among the highest incidence
of people with IBD, including Crohn's disease and UC, in the world. It is
estimated that there are over 230,000 individuals living with IBD in Canada,
including over 100,000 people living with UC.(2) Symptoms of UC may include:
bloody diarrhea, mild fever, abdominal pains and cramps, fatigue, loss of
appetite, weight loss, and pain and swelling in the joints.(2) UC can have a
range of implications for people's quality of life, including a negative
psycho-social impact and a substantial personal burden.(2)
The approval is supported by data from the Program of Ulcerative Colitis
Research Studies Utilizing an Investigational Treatment (PURSUIT) clinical
trials, evaluating patients with moderately to severely active UC who had
previously failed or were intolerant to conventional treatments. For the
treatment of UC, the SIMPONI(®) dose regimen consists of 200 mg
subcutaneously injected at week 0, followed by 100 mg at week 2 and then 50 mg
every 4 weeks, thereafter.The maintenance dose of 100 mg every 4 weeks can
be considered at the discretion of the treating physician. A significantly
greater proportion of patients who received SIMPONI(®) 200 mg/100 mg achieved
clinical response, clinical remission and improvement of the endoscopic
appearance of the mucosa at week 6 compared with patients receiving placebo.
Those patients who responded during induction were randomized into the
maintenance study where they were assessed every four weeks for clinical
response. The proportion of patients who maintained clinical response through
week 54 was significantly greater in the SIMPONI(®) 50 mg group and 100 mg
group compared with the placebo group.Additionally, the proportions of
patients who were in continuous clinical response and maintained sustained
remission (in remission at both weeks 30 and 54), and those who demonstrated
sustained improvement of endoscopic appearance of the mucosa at both weeks 30
and 54 were significantly greater in the SIMPONI(®) 100 mg group compared
with the placebo group.
"Effective treatment options are vital disease management tools for Canadians
who are living with ulcerative colitis," said Gail Attara, President and CEO,
Gastrointestinal Society. "Ensuring that these treatments are accessible to
those who will likely have a vast health benefit from them is also of
Canadians living with UC and prescribed treatment with SIMPONI(®) will
receive instruction and support from the BioAdvance(®*) Network of clinics,
located in centres across Canada, or through home injection services delivered
by BioAdvance(® )nurses.
The Program of Ulcerative Colitis Research Studies Utilizing an
Investigational Treatment (PURSUIT) included Phase 3 multicenter, randomized,
double-blind, placebo-controlled studies designed to evaluate the safety and
efficacy of subcutaneous induction and every-four-week maintenance regimens of
SIMPONI(®) in adults with moderately to severely active UC. All trial
patients had failed to respond to or tolerate treatment with 6-mercaptopurine
(6-MP), azathioprine (AZA), corticosteroids and/or 5-aminosalicylate (5-ASA),
or were corticosteroid dependent. Study participants were naïve to treatment
with TNF inhibitors and had a baseline Mayo score between 6 and 12 and
endoscopic subscore of 2 or more. The Mayo score is a 12-point clinical
assessment and colonoscopy-based measure of disease activity, which assesses
improvement in symptoms based on rectal bleeding, endoscopic findings, stool
frequency and a physician's global assessment.
The PURSUIT-Induction trial had an adaptive design with a Phase 2 dose-finding
portion followed by a Phase 3 dose-confirming component. The primary endpoint
was clinical response at week 6. Secondary endpoints at week 6 included
clinical remission and improved endoscopic appearance of the mucosa during
induction. Overall, 1,065 patients were treated in the study; 761 of these
patients were randomized into the Phase 3 component of the study.
Patients responding to induction treatment with SIMPONI(®) were eligible to
be randomized in the Phase 3 PURSUIT-Maintenance study. The primary endpoint
in this study was maintenance of clinical response through week 54, and
secondary endpoints included clinical remission and improvement of endoscopic
appearance of the mucosa at both weeks 30 and 54.
In both studies, clinical response, clinical remission and improvement of
endoscopic appearance of the mucosa were defined based on the Mayo score,
which consists of four subscores:stool frequency, rectal bleeding, findings
of endoscopy, and physician's global assessment.Each subscore is rated on a
scale from 0 to 3, indicating normal (0) to severe (3) activity.The Mayo
score is the sum of the four subscores.Clinical response was defined as a
decrease from week 0 of induction in the Mayo score of ≥ 30% and ≥ 3
points, accompanied by a decrease in the rectal bleeding subscore of ≥ 1 or
rectal bleeding subscore of 0 or 1.Clinical remission was defined as a Mayo
score ≤ 2 points, with no individual subscore >1.Improvement of endoscopic
appearance of the mucosa was defined as a Mayo endoscopy subscore of 0 (normal
or inactive disease) or 1 (erythema, decreased vascular pattern, mild
The safety results of SIMPONI(®) observed in the PURSUIT studies were
consistent with the known safety profile of SIMPONI(®) in labeled
About SIMPONI(®) (golimumab)
First approved by Health Canada in April 2009, SIMPONI(®), in combination
with methotrexate, is also indicated for reducing signs and symptoms and
improving physical function in adult patients with moderately to severely
active rheumatoid arthritis (RA), as well as inhibiting the progression of
structural damage in adult patients with moderately to severely active RA who
had not previously been treated with methotrexate. SIMPONI(®) is also
approved for reducing signs and symptoms, inhibiting the progression of
structural damage and improving physical function in adult patients with
moderately to severely active psoriatic arthritis, as well as reducing signs
and symptoms in adult patients with active ankylosing spondylitis who have had
an inadequate response to conventional therapies.(1)
SIMPONI(®) can lower the body's ability to fight infections. Serious
infections, including sepsis, tuberculosis, legionellosis (a serious form of
bacterial pneumonia), listeriosis (an infection that usually develops after
eating food contaminated by the bacteria listeria) and opportunistic
infections (such as systemic fungal and bacterial infections) have been
reported in patients receiving SIMPONI(®) and other similar medicines, and in
some cases have been fatal.
Please refer to the SIMPONI(®) Product Monograph for additional safety
information, including information regarding malignancies, congestive heart
failure, neurologic events and hematologic warnings, and for complete
prescribing information( )available at www.janssen.ca.
About Janssen Inc.
As a member of the Janssen Pharmaceutical Companies, Janssen Inc. is dedicated
to addressing and solving the most important unmet medical needs in pain
management, psychiatry, oncology, immunology, psoriasis, virology, anemia,
attention deficit hyperactivity disorder, gastroenterology and women's health.
Driven by our commitment to the passionate pursuit of science for the benefit
of patients, we work together to bring innovative ideas, products and services
to patients around the world.
*All trademark rights used under license.
(1) SIMPONI(®) Product Monograph, Janssen Inc., 2013. Available at
(2) "The Impact of Inflammatory Bowel Disease (IBD) in Canada - 2012 Final
Report and Recommendations," Crohn's and Colitis Foundation of Canada,
accessed May 3, 2013,
SOURCE Janssen Inc.
or to arrange an interview, please contact:
Jennifer McCormack Janssen Inc. 416-449-9444 firstname.lastname@example.org
Laine Jaremey GCI Group 416-486-7224 email@example.com
To view this news release in HTML formatting, please use the following URL:
CO: Janssen Inc.
-0- Sep/24/2013 11:00 GMT
Press spacebar to pause and continue. Press esc to stop.